readthroughSign in
CompanyINDPNasdaqNew York, NY

Indaptus Therapeutics, Inc

Indaptus Therapeutics develops the Decoy platform, which uses attenuated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immunity while reducing systemic toxicity.

6-KNov 16Latest SEC filing
Nov 16Latest story